European Heart Journal

European Heart Journal Journal

Publication venue for

Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction 2024
End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study 2023
Testosterone and cardiovascular health 2023
Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness? 2023
Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. 42:2588-2588. 2021
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants among nonvalvular atrial fibrillation patients with prior bleeding events. 42:572-572. 2021
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among nonvalvular atrial fibrillation patients with prior bleeding events. 42:571-571. 2021
Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin. 42:573-573. 2021
Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: an ARISTOPHANES analysis. 42:574-574. 2021
Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men. 41:1503. 2020
Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?. 41:3092-3093. 2020
Are changes in telomerase activity and telomere length due to different exercise modalities, intensity, or methods: intermittency?. 40:3198-3199. 2019
Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study. 40:2972-2972. 2019
Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis. 40:2998-2998. 2019
Is the PURE study pure fiction?. 40:394-394. 2019
Promoting physical activity in primary and secondary prevention. 40:3556-3558. 2019
Autologous CD34(+) cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. 39:2208-2216. 2018
Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis An Expert Statement. 39:1224-1245. 2018
Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study. 39:612-613. 2018
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. 39:610-611. 2018
Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study. 39:505-505. 2018
Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study. 39:506-506. 2018
Disproving the obesity paradox-not. 39:3672-3672. 2018
Obesity survival paradox in patients with acute pulmonary embolism. 39:497-497. 2018
Personalized exercise dose prescription. 39:2346-2355. 2018
Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis. 38:767-767. 2017
Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis. 38:772-772. 2017
Impact of prior cerebrovascular diseases on treatment strategies and clinical outcomes after percutaneous coronary interventions. 38:76-76. 2017
Real-world comparison of major bleeding risk associated with direct oral anticoagulants or warfarin in patients with non-valvular atrial fibrillation: a systematic review and network meta-analysis. 38:577-578. 2017
Time-varying circulating biomarkers predict ventricular tachyarrhythmia and death: the LIFEMARKER-VT study. 38:1377-1377. 2017
Cardiac follow-up of cancer survivors. 37:2745-2747. 2016
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. 37:3600-3609. 2016
Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. 37:503-504. 2016
Hospitalizations and other healthcare resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting. 37:784-785. 2016
Physical activity, body mass index and mortality among subjects with coronary heart disease. 37:992-993. 2016
Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US. 36:1083-1083. 2015
Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. 36:2373-2380. 2015
Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants. 36:338-338. 2015
Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. 32:2231-U102. 2011
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. 30:2908-2914. 2009

International Standard Serial Number (ISSN)

0195-668X